Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 3,540 shares at $78.23 ($280K) on 2026-05-08, disclosed to the SEC on 2026-05-12.
Scheduled sale ($280k) by Executive VP AND CLO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $78.00 | 200 | $16K | 5.6% |
| 2 | $78.23 | 840 | $66K | 23.5% |
| 3 | $79.28 | 600 | $48K | 17.0% |
| 4 | $79.31 | 1,900 | $151K | 53.9% |
| Total | $78.97 avg | 3,540 | $280K | 100% |
| Filing → |
| PTCT | SELL | 2026-07-08 | $432K | — | Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |
| PTCT | SELL | 2026-05-19 | $203K | — | Filing → |